Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more »Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
Stray dogs in short supply as students rush in to walk them – at what risks?
Turning 60 but still working? How to encourage China’s retirees back to work
Sunday
- Subscribe
Related News
NZ experts to implant pig cells in diabetics
Source: Agencies |
July 24, 2009, Friday
|
Print Edition
Print Edition
A NEW Zealand biotech firm began a trial yesterday that will implant cells from newborn pigs into eight human volunteers as an experimental treatment for their diabetes.
The cells produce pig insulin, which is similar to human insulin and has the same effect of lowering blood sugar, and Living Cell Technologies hopes the cells may be able to delay the effects of Type 1 - diabetes blindness, premature coronary illness and limb amputation.
Though Professor Bob Elliott, medical director of the company, acknowledges that even in the best-case scenario the treatment would not eliminate all of the symptoms.
But some scientists have warned that implanting pig cells carries the risk of introducing a new virus to humans. Others have noted that it is too soon to begin testing on humans because no animal trials were conducted.
Elliott said yesterday that the risk of a pig endogenous retrovirus - the porcine virus thought to be most contagious for humans - infecting humans is largely "theoretical."
"There is no evidence of a risk" of retrovirus infection.
The piglets being used, recovered from 150 years of isolation on islands south of New Zealand, carried no known agent that could infect humans and are held in a fully closed, sterile environment.
Yesterday, endocrinologist John Baker at Middlemore Hospital in Auckland began monitoring the first volunteer who will receive the pig cells. They will be implanted after two months, Elliott said. The company will then wait several months before implanting cells in a second volunteer.
The cells will be coated in a seaweed-derived membrane to discourage the volunteers' immune systems from rejecting them. Due to the coating, the participants will not use immunosuppressant drugs.
The eight trial patients suffer from a very unstable, severe or "brittle" form of diabetes and were chosen from a pool of 1,000 volunteers.
The cells produce pig insulin, which is similar to human insulin and has the same effect of lowering blood sugar, and Living Cell Technologies hopes the cells may be able to delay the effects of Type 1 - diabetes blindness, premature coronary illness and limb amputation.
Though Professor Bob Elliott, medical director of the company, acknowledges that even in the best-case scenario the treatment would not eliminate all of the symptoms.
But some scientists have warned that implanting pig cells carries the risk of introducing a new virus to humans. Others have noted that it is too soon to begin testing on humans because no animal trials were conducted.
Elliott said yesterday that the risk of a pig endogenous retrovirus - the porcine virus thought to be most contagious for humans - infecting humans is largely "theoretical."
"There is no evidence of a risk" of retrovirus infection.
The piglets being used, recovered from 150 years of isolation on islands south of New Zealand, carried no known agent that could infect humans and are held in a fully closed, sterile environment.
Yesterday, endocrinologist John Baker at Middlemore Hospital in Auckland began monitoring the first volunteer who will receive the pig cells. They will be implanted after two months, Elliott said. The company will then wait several months before implanting cells in a second volunteer.
The cells will be coated in a seaweed-derived membrane to discourage the volunteers' immune systems from rejecting them. Due to the coating, the participants will not use immunosuppressant drugs.
The eight trial patients suffer from a very unstable, severe or "brittle" form of diabetes and were chosen from a pool of 1,000 volunteers.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
